Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiology News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Heart CARE for diabetics: Updated results from Medtronic's 813-patient CARE-HF study finds Medtronic's cardiac resynchronization therapy (CRT) is equally effective for diabetic and nondiabetic heart failure patients. CRT reduced the all-cause mortality rate in diabetic patients by 39%, compared with a 40% reduction in nondiabetics, the firm reported Sept. 3 at the European Society of Cardiology/World Congress of Cardiology 2006 meeting in Barcelona. Overall, Medtronic's InSync CRT products reduced the risk of heart failure death by 45% and sudden cardiac death by 53% in the study, which randomized patients to medical management with and without CRT, with an average follow-up period of about 36 months (1"The Gray Sheet" March 14, 2005, p. 7)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT023961

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel